

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5942056

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
TANJA FAUTI	11/28/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ROCHE GLYCART AG
<b>Street Address:</b>	WAGISTRASSE 10
<b>City:</b>	SCHLIEREN
<b>State/Country:</b>	SWITZERLAND
<b>Postal Code:</b>	8952
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16721272
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	650-467-8720
<b>Email:</b>	kokkac@gene.com
<b>Correspondent Name:</b>	CHIAKI KOKKA
<b>Address Line 1:</b>	1 DNA WAY
<b>Address Line 4:</b>	SOUTH SAN FRANCISCO, CALIFORNIA 94080
<b>ATTORNEY DOCKET NUMBER:</b>	P35128-US
<b>NAME OF SUBMITTER:</b>	CHIAKI KOKKA
<b>SIGNATURE:</b>	/Chiaki Kokka/
<b>DATE SIGNED:</b>	02/03/2020
<b>Total Attachments: 3</b>	
source=Assignment 9 (P35128-EP-1 GLYCART Inventor FAUTI to GLYCART)#page1.tif	
source=Assignment 9 (P35128-EP-1 GLYCART Inventor FAUTI to GLYCART)#page2.tif	
source=Assignment 9 (P35128-EP-1 GLYCART Inventor FAUTI to GLYCART)#page3.tif	

**ASSIGNMENT AGREEMENT**

I/We, the undersigned

**Inventor(s)**

Tanja FAUTI, a German citizen  
c/o Roche Glycart AG  
Wagistrasse 10  
8952 Schlieren, Switzerland

**Employed by:**

Roche Glycart AG

hereinafter ASSIGNOR(S), herewith declare that I am/we are joint inventor(s) together with

**Inventor(s)**

Guy GEORGES  
Thomas HOFER  
Ralf HOSSE  
Christian KLEIN  
Ekkehard MOESSNER  
Johannes SAM  
Pablo UMANA  
Jenny THOM  
Stephan GASSER

**Employed by:**

Roche Diagnostics GmbH  
Roche Glycart AG  
Roche Glycart AG  
Roche Glycart AG  
Roche Glycart AG  
Roche Glycart AG  
Roche Glycart AG  
Roche Glycart AG  
Roche Glycart AG

hereinafter CO-INVENTOR(S)

of the invention entitled:

**Tumor-targeted agonistic CD28 antigen binding molecules**

disclosed in patent application(s) to be filed in certain countries of the world claiming priority of the patent(s) or patent application(s) filed as listed below and for which I/we am/were not named as inventor(s)

**European Patent Office**  
as outlined below:

Case No.	Country	Filing Date	Serial No.
P35128-EP	Europe	December 21, 2018	18215121.7
P35128-EP-1	Europe	September 06, 2019	19196006.1

ASSIGNOR(S) acknowledge(s) the previous transfer to

Roche Glycart AG  
Wagistrasse 10  
8952 Schlieren  
Switzerland

hereinafter ASSIGNEE, of all right, title, and interest in, to, and deriving from the invention(s) disclosed by ASSIGNOR(S) in patent application(s) to be filed in certain countries of the world claiming priority of the patent or patent application(s) filed as listed above, by operation of law, contract, or otherwise.

As far as right, title, and interest of the ASSIGNOR(S) in, to, and deriving from the invention(s) disclosed by ASSIGNOR(S) in patent application(s) to be filed in certain countries of the world claiming priority of the patent or patent application(s) filed as listed above may not have been transferred to ASSIGNEE, ASSIGNOR(S) herewith assign(s) to ASSIGNEE all right, title, and interest

in, to, and deriving from the invention(s) disclosed by ASSIGNOR(S) in patent application(s) to be filed in certain countries of the world claiming priority of the patent or patent application(s) filed as listed above, including the right to claim priority.

ASSIGNEE by virtue of this assignment thereof shall have the exclusive right and is fully entitled to apply for, obtain, and own patents and patent application worldwide in its own name and at its own costs that

- a) claim priority to and are based in whole or in part on the patent or patent application(s) set forth above for which priority is claimed and
- b) claim priority to and are based in whole or in part on any patent and patent application(s) to be filed in certain countries of the world which are based on the application(s) set forth above for which priority is claimed,

to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.

ASSIGNEE and ASSIGNOR hereby acknowledge, confirm, and agree that ASSIGNOR has been fully and adequately compensated for all rights granted or assigned to ASSIGNEE hereunder.

This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated, April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

**ASSIGNOR(S)**

Schliener 28.11.2019  
Schliener, Switzerland,

Tanja FAUTI

**ASSIGNEE**

Roche Glycart AG

Basel, Switzerland, December 4, 2019  
Ina Gengelbach Petra Querfeld  
both authorized signatories

## Legalization

The undersigned Notary Public of the Canton of Basel-Stadt (Switzerland), Dr. Christoph Nertz, herewith legalizes the overleaf signature of

Miss Tanja Fauti, born on November 22<sup>nd</sup>, 1976, German citizen, residing in Zürich (Switzerland),

He certifies that the named person is in the employ of Roche Glycart AG, a stock company with legal domicile in Schlieren (Switzerland),

Legalization based on comparison with authentic signatures.

He also legalizes the overleaf signature of

Roche Glycart AG, a stock company with legal domicile in Schlieren (Switzerland), rendered by


Miss Ina Gengelbach, German citizen, residing in Grenzach-Wyhlen (Germany), and

Miss Petra Querfeld, German citizen, residing in Steinen (Germany),

both duly entitled to sign documents wherein property of the company is alienated.

Signers and signatures personally known.

B a s e l (Switzerland), this 5<sup>th</sup> (fifth) day of December 2019 (two thousand and nineteen).



BR 1451/2019